GH Research to Present at ASCP Meeting on Depression Treatments

GH Research ( (GHRS) ) has shared an announcement.

GH Research PLC announced its participation in the upcoming American Society of Clinical Psychopharmacology Annual Meeting from May 27-30, 2025, in Scottsdale, Arizona. The company will present findings from its clinical trials on GH001, a treatment for depression, highlighting its safety and efficacy in treatment-resistant depression and postpartum depression. This participation underscores GH Research’s commitment to advancing mental health treatments and may enhance its standing in the psychopharmacology sector.

The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC operates in the pharmaceutical industry, focusing on developing treatments for mental health disorders. The company is particularly involved in researching and developing innovative therapies for treatment-resistant depression, utilizing compounds like mebufotenin for pulmonary inhalation.

Average Trading Volume: 217,448

Technical Sentiment Signal: Strong Buy

Current Market Cap: $725.7M

For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.